Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.
Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.
Rhythm Pharmaceuticals has appointed Pamela Cramer as Chief Human Resources Officer and Linda Shapiro Manning, M.D., Ph.D. as Senior Vice President, Clinical, as of July 26 and earlier in July, respectively. Cramer brings 20 years of experience in HR from notable companies, while Shapiro has over 20 years in obesity medicine, including leadership roles in clinical development. These appointments come as the company seeks to expand the reach of its first FDA-approved therapy, IMCIVREE (setmelanotide), aimed at treating rare genetic obesity disorders.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a research agreement with CRIBBS to study the natural history of weight gain and quality of life in patients with Bardet-Biedl syndrome (BBS). This study aims to analyze health outcomes related to severe obesity and hyperphagia, involving over 600 patients. Rhythm estimates that BBS affects approximately 1,500 to 2,500 individuals in the U.S. The collaboration seeks to improve care and develop tailored treatment solutions for affected individuals.
Rhythm Pharmaceuticals (RYTM) will hold a live conference call on August 3, 2021, at 8:00 a.m. ET to discuss its Q2 2021 financial results and provide a corporate update. The company focuses on therapies for rare genetic obesity diseases and has launched IMCIVREE (setmelanotide), the first FDA-approved treatment for specific genetic obesity conditions. The drug received EU approval in July 2021. Rhythm's proprietary database includes approximately 37,500 genetic samples to advance understanding of obesity genetics.
Rhythm Pharmaceuticals announced that the European Commission has granted marketing authorization for IMCIVREE (setmelanotide), the first treatment for rare genetic obesity diseases in the EU. This approval covers patients with genetically confirmed POMC, PCSK1, or LEPR deficiencies aged 6 and older. Phase 3 trials showed significant weight loss—80% of patients with POMC or PCSK1 deficiency achieved over 10% weight loss. IMCIVREE is designed to address severe hunger and obesity by restoring the functioning of the MC4 receptor pathway, aiming to improve patients' quality of life.
Rhythm Pharmaceuticals (Nasdaq: RYTM) has announced an exclusive distribution agreement with Medison Pharma to commercialize its MC4 receptor agonist, IMCIVREE™ (setmelanotide), in Israel. IMCIVREE is FDA-approved for chronic weight management in patients aged 6 and older with obesity due to specific genetic deficiencies, notably POMC, PCSK1, or LEPR. This partnership aims to expand access for patients with rare genetic obesity conditions, leveraging Medison's expertise in navigating the registration and reimbursement landscape.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that its CEO, Dr. David Meeker, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 12 noon ET. A live audio webcast will be available on the Company's website under ‘Events & Presentations’. Rhythm is focused on therapies for rare genetic diseases of obesity and has developed IMCIVREE™ (setmelanotide), the first FDA-approved treatment for specific genetic obesity conditions. The company is based in Boston, MA.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding marketing authorization for setmelanotide. This treatment targets severe obesity and insatiable hunger linked to confirmed genetic deficiencies (POMC, PCSK1, LEPR) in adults and children over 6. The final decision by the European Commission is expected in July 2021. Two pivotal trials demonstrated significant weight loss and hunger reduction, highlighting setmelanotide's potential as the first approved treatment in the EU for these conditions.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that David Meeker, M.D., will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 4:15 p.m. ET. A live audio webcast will be available on the company's investor relations website, with a replay accessible for 30 days following the event.
Rhythm focuses on treating rare genetic diseases of obesity and has FDA-approved IMCIVREE™ (setmelanotide) for chronic weight management in patients aged six and older with specific genetic deficiencies.
Rhythm Pharmaceuticals reported promising developments in Q1 2021, including the first U.S. commercial sales of IMCIVREE™ (setmelanotide), which occurred late in March. The company showcased significant weight loss results in clinical trials for individuals with rare genetic obesity disorders. Financially, Rhythm raised $172.5 million through a public offering and generated $35,000 in product revenues. The net income for the quarter was $43.8 million, reversing a loss from the previous year. The cash position improved to $404.8 million, providing ample funding to sustain operations into 2023.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that David Meeker, M.D., will participate in a fireside chat at the 20th Annual Needham & Co. Virtual Healthcare Conference on April 14, 2021, at 11:45 a.m. ET. A live audio webcast will be accessible on the company’s website, with a replay available for 30 days after the event.
The company focuses on therapies for rare genetic diseases of obesity, featuring its FDA-approved precision medicine, IMCIVREE™ (setmelanotide), for chronic weight management in eligible patients.